Serial Number 87817994
602

Registration Progress

Application Filed
Mar 2, 2018
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

Basic Information

Serial Number
87817994
Filing Date
March 2, 2018
Abandonment Date
July 8, 2019
Drawing Code
2

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Aug 2, 2019
Classes
042

Rights Holder

Protagonist Therapeutics, Inc.

03
Address
Suite 140
7707 Gateway Blvd.
Newark, CA 94560

Ownership History

Protagonist Therapeutics, Inc.

Original Applicant
03
Newark, CA

Legal Representation

Attorney
DAVID A. JACKSON

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

15 events
Date Code Type Description Documents
Aug 2, 2019 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Aug 2, 2019 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Jan 4, 2019 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Jan 4, 2019 GNFR O FINAL REFUSAL E-MAILED Loading...
Jan 4, 2019 CNFR R FINAL REFUSAL WRITTEN Loading...
Dec 17, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 17, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 17, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 18, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 18, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 18, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 14, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 10, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Mar 9, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 6, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific research, pharmaceutical research, medical research; technical and scientific consultation and product development services, including for others, in the fields of immune mediated diseases, inflammatory diseases, and rare diseases; research and development of new products pertaining to the treatment of immune mediated diseases, inflammatory diseases, and rare diseases, and to pharmaceuticals; providing on line information for medical research purposes, in the fields of immune mediated diseases, inflammatory diseases, and rare diseases, treatments for immune mediated diseases, inflammatory diseases, and rare diseases, and pharmaceuticals

Additional Information

Design Mark
The mark consists of DNA double helix, with the left-hand helix in black and the right-hand helix in orange.
Color Claim
The color(s) black and orange is/are claimed as a feature of the mark.

Classification

International Classes
042